摘要
目的了解TEC新辅助化疗方案在局部晚期乳腺癌治疗前后ER、PR、c-erbB-2的变化,探讨其与新辅助化疗疗效之间的相关关系。方法 2005年3月至2009年10月,我们共收集了46例局部晚期乳腺癌患者。患者化疗前行乳腺肿瘤粗针穿刺活检并免疫组化方法检测肿瘤ER、PR+、c-erbB-2的表达。随后进行3个疗程化疗,化疗方案为多西紫衫醇75mg/m2iv,d1;表阿霉素75mg/m2iv,d1;环磷酰胺500mg/m2iv,d1;q21。化疗后评估疗效并对接受手术的患者的手术标本通过同法检测生物学因子的表达。结果新辅助化疗前后ER、PR、c-erbB-2均发生了改变,新辅助化疗前ER和PR阴性表达的肿瘤组织新辅助化疗后上调(ER:22.92%vs.18.83%;PR:20.83%vs.14.58%),但没有统计学意义。结论新辅助化疗可以改变ER、PR、c-erbB-2的表达,本临床研究未发现ER、PR、c-erbB-2变化与局部晚期乳腺癌的新辅助化疗有相关关系。
Objective To clarify the changes of expressions of ER, PR and c-erbB-2 by the neoadjuvant chemotherapy. To investigate relationship between the expressions of ER, PR and c-erbB-2 with the effective rate of neoadjuvant chemotherapy for locally advanced breast cancer（LABC）. Methods From March 2005 to October 2009, 46 patients Received TEC chemotherapy before operation. All the patients took The TEC regimen （TEC, every 3 weeks for three cycles before operation）, The diagnosis was proved by core biopsy. The expressions of ER, PR and c-erbB-2 were measured by IHC in the neoadjuvant chemotherapy biopsy specimens and postoperative tumor tissue. Results The expressions of ER, PR and c-erbB-2 have changed at different levels. ER and PR negative tumor more likely to be changed into positive expression after neoadjuvant chemotherapy than that of positive changed into negative（ER：22.92% vs. 18.83%; PR：20.83% vs. 14.58%, P0.05）. Conclusion The neoadjuvant chemotherapy can modulate the expression of ER, PR and c-erbB-2. The relationship between the changing of ER, PR and c-erbB-2 expression and neoadjuvant chemotherapy for LABC is not clear.
出处
《中国医药指南》
2010年第34期186-188,共3页
Guide of China Medicine
关键词
局部晚期乳腺癌
新辅助化疗
生物学因子
Locally advanced breast cancer
Neoadjuvant chemotherapy
Biomarker
